Table 1.
Patients’ clinicopathologic characteristics.
| Characteristics | Missing Rate (%) | All (n = 1002, %) | Platinum-Sensitive (n = 779, %) |
Platinum-Resistant (n = 223, %) |
p |
|---|---|---|---|---|---|
| Age, years | 0 | 55.8 ± 10 | 55.2 ± 10 | 58.3 ± 10 | <0.001 |
| BMI, kg/m2 | 3.2 | 23.6 ± 3 | 23.5 ± 3 | 23.9 ± 3 | 0.135 |
| Parity | 0.9 | 0.884 | |||
| 0 | 97 (9.8) | 77 (10.0) | 20 (9.1) | ||
| 1–2 | 592 (59.6) | 458 (59.2) | 134 (60.9) | ||
| ≥3 | 304 (30.6) | 238 (30.8) | 66 (30.0) | ||
| Menopause | 0.4 | 691 (69.2) | 513 (66.1) | 178 (80.2) | <0.001 |
| Comorbidities | |||||
| Hypertension | 22.2 | 153 (19.6) | 107 (18.1) | 46 (24.5) | 0.069 |
| Diabetes | 22.2 | 53 (6.8) | 36 (6.1) | 17 (9.0) | 0.215 |
| Dyslipidemia | 22.3 | 35 (4.5) | 29 (4.9) | 6 (3.2) | 0.431 |
| Personal history of breast cancer | 3.3 | 72 (7.4) | 59 (7.8) | 13 (6.0) | 0.453 |
| Familial history of breast cancer * | 5.5 | 51 (5.4) | 42 (5.7) | 9 (4.2) | 0.486 |
| No. of family members with cancer | |||||
| Median (range) | 5.5 | 0 (0–3) | 0 (0–3) | 0 (0–2) | 0.295 |
| Familial history of gynecologic cancer * | 5.5 | 21 (2.2) | 18 (2.5) | 3 (1.4) | 0.511 |
| No. of family members with cancer | |||||
| Median (range) | 5.5 | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0.702 |
| Origin | 0 | 0.532 | |||
| Ovary | 911 (90.9) | 708 (90.9) | 203 (91.0) | ||
| Tube | 51 (5.1) | 42 (5.4) | 9 (4.0) | ||
| Peritoneum | 40 (4.0) | 29 (3.7) | 11 (4.9) | ||
| FIGO stage | 0 | <0.001 | |||
| I | 40 (4.0) | 40 (5.1) | 0 | ||
| II | 56 (5.6) | 54 (6.9) | 2 (0.9) | ||
| III | 628 (62.7) | 496 (63.7) | 132 (59.2) | ||
| IV | 278 (27.7) | 189 (24.3) | 89 (39.9) | ||
| Ln (Serum CA-125 [IU/mL]) | 4.3 | 6.7 ± 2 | 6.6 ± 2 | 7.1 ± 1 | <0.001 |
| Hemoglobin (g/dL) | 11.9 | 12.3 ± 1 | 12.3 ± 1 | 12.2 ± 1 | 0.192 |
| Primary treatment strategy | 0 | <0.001 | |||
| PDS | 764 (76.2) | 629 (80.7) | 135 (60.5) | ||
| NAC | 238 (23.8) | 150 (19.3) | 88 (39.5) | ||
| Residual tumor size after PDS/IDS | 4.4 | <0.001 | |||
| Complete cytoreduction | 549 (57.3) | 455 (61.2) | 94 (43.9) | ||
| Gross residual tumor | 409 (42.7) | 289 (38.8) | 120 (56.1) | ||
| Frontline chemotherapy regimen | 4.0 | 0.870 | |||
| Paclitaxel-Carboplatin | 872 (90.6) | 676 (90.5) | 196 (91.2) | ||
| Docetaxel-Carboplatin | 90 (9.4) | 71 (9.5) | 19 (8.8) | ||
| Total cycle of frontline chemotherapy | 0 | <0.001 | |||
| ≤6 | 694 (69.3) | 564 (72.4) | 130 (58.3) | ||
| >6 | 308 (30.7) | 215 (27.6) | 93 (41.7) | ||
| Recurrence | 0 | 734 (73.3) | 511 (65.6) | 223 (100.0) | <0.001 |
| Treatment-free interval, months | 0 | ||||
| Median (range) | 12.9 (0.1–153.4) | 17.2 (6.1–153.4) | 3.4 (0.1–6.0) | <0.001 |
Data are presented as mean ± standard deviation for continuous variables and as count (%) for categorical variables. Abbreviations: BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery. * Up to second degree.